KPTI
Karyopharm Therapeutics Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
0.68
▲ 0.01 (1.42%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.67
Prev close
0.67
Day high
0.72
Day low
0.64
Volume
1.18M
Market cap
$14.74M
P/E (TTM)
—
52W range
0.63 – 10.99
Day trading desk
Gap from prior close
-0.00%
Prior close 0.67
VWAP
0.67
+0.96% from price
Relative volume
0.71×
Normal
Session range
12.56%
0.64 – 0.71
Position in range
56%
Mid range
ATR (14D)
0.18
26.84% of price
Prior day high
0.80
PDH
Prior day low
0.63
PDL
Bid / ask spread
—
Quote not published
Session volume
1.21M
Avg 1.71M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-46.06%
-48.0%
1M
-63.69%
-64.8%
3M
-93.91%
-98.4%
6M
-90.98%
-109.2%
YTD
-91.17%
-105.4%
1Y
-89.81%
-106.2%
3Y
-96.77%
-179.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KPTI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+97.27K
Net buying
Buy transactions
12
101.58K shares
Sell transactions
9
4.31K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
1.06M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | ABATE KRISTIN Officer |
SELL | 19 | $38 | Direct |
| Jul 28, 26 | POULTON STUART Officer |
SELL | 189 | $1.34K | Direct |
| May 21, 26 | BOHLIN GAREN G. Director |
STOCK | 15.51K | $0 | Direct |
| May 21, 26 | OLIGER CHRISTY J Director |
STOCK | 15.51K | $0 | Direct |
| May 21, 26 | SU ZHEN Director |
STOCK | 15.51K | $0 | Direct |
| May 21, 26 | GREENE BARRY E Director |
STOCK | 15.51K | $0 | Direct |
| May 21, 26 | PAKIANATHAN DEEPIKA R Director |
STOCK | 15.51K | $0 | Direct |
| May 21, 26 | SCHOR CHEN Director |
STOCK | 15.51K | $0 | Direct |
| May 14, 26 | PAULSON RICHARD A. Chief Executive Officer |
SELL | 2.20K | $20.93K | Direct |
| May 14, 26 | RANGWALA RESHMA Officer |
SELL | 408 | $3.88K | Direct |
| May 14, 26 | MANO MICHAEL Officer |
SELL | 266 | $2.53K | Direct |
| May 14, 26 | CHENG SOHANYA ROSHAN Officer |
SELL | 324 | $3.08K | Direct |
| May 14, 26 | POULTON STUART Officer |
SELL | 403 | $3.83K | Direct |
| May 14, 26 | ABATE KRISTIN Officer |
SELL | 53 | $504 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABATE KRISTIN |
Officer | 23.78K | Sale |
BOHLIN GAREN G. |
Director | 18.52K | Stock Award(Grant) |
CHENG SOHANYA ROSHAN |
Officer | 107.94K | Sale |
GREENE BARRY E |
Director | 16.41K | Stock Award(Grant) |
MACOMBER LORI A |
Chief Financial Officer | 85.11K | Sale |
MANO MICHAEL |
Officer | 94.40K | Sale |
PAKIANATHAN DEEPIKA R |
Director | 15.51K | Stock Award(Grant) |
PAULSON RICHARD A. |
Chief Executive Officer | 269.75K | Sale |
POULTON STUART |
Officer | 94.63K | Sale |
RANGWALA RESHMA |
Officer | 56.83K | Sale |
Fundamentals
Market cap$14.74M
Enterprise value$278.17M
Revenue (TTM)$146.62M
Gross profit$145.25M
EBITDA$-82.20M
Net income$-224.74M
EPS (TTM)$-13.93
Free cash flow$-29.67M
Total cash$65.11M
Total debt$328.53M
Book value / share$-14.56
Shares outstanding22.68M
Float16.01M
Short % of float34.85%
Dividend yield0.00%
Beta (5Y)1.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.23
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.90
EV / EBITDA-3.38
Gross margin99.06%
Operating margin-67.38%
Profit margin-153.28%
Return on equity—
Return on assets-47.61%
Debt / equity—
Current ratio0.79
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $146.07M | $145.24M | $146.03M | $157.07M | +0.6% |
| Operating revenue | $146.07M | $145.24M | $146.03M | $157.07M | +0.6% |
| Cost of revenue | $5.95M | $6.01M | $4.94M | $5.21M | -1.0% |
| Gross profit | $140.12M | $139.23M | $141.09M | $151.86M | +0.6% |
| Research & development | $125.62M | $143.23M | $138.75M | $148.66M | -12.3% |
| Selling, general & admin | $105.21M | $115.44M | $131.88M | $145.40M | -8.9% |
| Total operating expense | $230.82M | $258.67M | $270.63M | $294.06M | -10.8% |
| Operating income | -$90.71M | -$119.44M | -$129.54M | -$142.20M | +24.1% |
| Net interest income | -$43.08M | -$30.02M | -$12.88M | -$22.64M | -43.5% |
| Pre-tax income | -$196.00M | -$76.36M | -$142.78M | -$164.92M | -156.7% |
| Tax provision | $43.00K | $57.00K | $323.00K | $369.00K | -24.6% |
| Net income | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -156.5% |
| Net income to common | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -156.5% |
| Basic EPS | -17.93 | -9.45 | -18.79 | -30.30 | -89.7% |
| Diluted EPS | -17.93 | -13.95 | -18.79 | -30.30 | -28.5% |
| EBIT | -$150.15M | -$38.94M | -$118.95M | -$139.93M | -285.6% |
| EBITDA | -$149.85M | -$38.60M | -$118.42M | -$139.31M | -288.2% |
| Basic shares | 10.94M | 8.12M | 7.62M | 5.46M | +34.6% |
| Diluted shares | 10.94M | 8.45M | 7.62M | 5.46M | +29.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $60.54M | $62.48M | $52.23M | $135.19M | -3.1% |
| Cash & short-term investments | $63.74M | $108.71M | $191.44M | $277.97M | -41.4% |
| Accounts receivable | $26.18M | $30.77M | $26.96M | $47.09M | -14.9% |
| Inventory | $4.04M | $4.74M | $3.04M | $4.22M | -14.8% |
| Total current assets | $103.15M | $156.46M | $233.92M | $350.16M | -34.1% |
| Property, plant & equipment | $4.65M | $6.28M | $4.88M | $7.38M | -26.0% |
| Total assets | $108.42M | $164.42M | $240.44M | $358.17M | -34.1% |
| Total current liabilities | $92.06M | $92.26M | $69.48M | $65.91M | -0.2% |
| Current debt | $21.01M | $24.43M | — | — | -14.0% |
| Long-term debt | $205.88M | $162.95M | $170.92M | $170.10M | +26.4% |
| Total debt | $233.61M | $194.52M | $177.02M | $179.07M | +20.1% |
| Total liabilities | $401.34M | $350.44M | $376.64M | $374.83M | +14.5% |
| Retained earnings | -$1.76B | -$1.56B | -$1.49B | -$1.34B | -12.5% |
| Shareholder equity | -$292.93M | -$186.02M | -$136.21M | -$16.66M | -57.5% |
| Working capital | $11.09M | $64.20M | $164.44M | $284.25M | -82.7% |
| Net tangible assets | -$292.93M | -$186.02M | -$136.21M | -$16.66M | -57.5% |
| Shares issued | 18.31M | 8.41M | 7.66M | 7.55M | +117.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$196.04M | -$76.42M | -$143.10M | -$165.29M | — | -156.5% |
| Depreciation & amortisation | $296.00K | $340.00K | $530.00K | $621.00K | — | -12.9% |
| Stock-based compensation | $14.05M | $18.43M | $21.71M | $35.40M | — | -23.7% |
| Change in working capital | $28.27M | -$302.00K | $31.42M | -$19.99M | — | +9,461.6% |
| Operating cash flow | -$75.37M | -$127.49M | -$92.72M | -$149.55M | — | +40.9% |
| Capital expenditure | — | -$142.00K | — | -$118.00K | -$5.71M | — |
| Investing cash flow | $43.38M | $95.47M | $7.94M | -$104.26M | — | -54.6% |
| Financing cash flow | $30.05M | $41.65M | $1.12M | $193.74M | — | -27.8% |
| Free cash flow | -$75.37M | -$127.63M | -$92.72M | -$149.67M | — | +40.9% |
| End cash position | $60.89M | $62.81M | $53.19M | $136.88M | — | -3.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $33.43M | $35.07M | $34.08M | $44.04M | $37.93M | -4.7% |
| Operating revenue | $33.43M | $35.07M | $34.08M | $44.04M | $37.93M | -4.7% |
| Cost of revenue | $1.08M | $1.34M | $1.48M | $2.11M | $1.05M | -19.3% |
| Gross profit | $32.35M | $33.72M | $32.59M | $41.93M | $36.88M | -4.1% |
| Research & development | $28.96M | $33.80M | $27.67M | $30.54M | $32.79M | -14.3% |
| Selling, general & admin | $25.92M | $26.68M | $22.77M | $26.61M | $28.48M | -2.9% |
| Total operating expense | $54.87M | $60.48M | $50.44M | $57.15M | $61.27M | -9.3% |
| Operating income | -$22.53M | -$26.76M | -$17.84M | -$15.22M | -$24.39M | +15.8% |
| Net interest income | -$12.42M | -$12.04M | -$12.01M | -$10.46M | -$10.62M | -3.2% |
| Pre-tax income | -$67.02M | -$22.39M | -$102.27M | -$33.09M | -$37.21M | -199.3% |
| Tax provision | $0 | $1.00K | -$67.00K | $34.00K | $40.00K | -100.0% |
| Net income | -$67.02M | -$22.39M | -$102.20M | -$33.13M | -$37.25M | -199.3% |
| Net income to common | -$67.02M | -$22.39M | -$102.20M | -$33.13M | -$37.25M | -199.3% |
| Basic EPS | -2.32 | -1.02 | -5.71 | -3.82 | -4.32 | -127.5% |
| Diluted EPS | -2.32 | -1.24 | -5.71 | -3.82 | -4.32 | -87.1% |
| EBIT | -$53.88M | -$9.84M | -$89.65M | -$22.09M | -$25.98M | -447.7% |
| EBITDA | -$53.88M | -$9.83M | -$89.63M | -$21.96M | -$25.91M | -448.3% |
| Basic shares | 28.94M | 22.01M | 17.90M | 8.67M | 8.62M | +31.5% |
| Diluted shares | 28.94M | 24.71M | 17.90M | 8.67M | 8.62M | +17.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.98M | $90.85M | $60.54M | $37.67M | $38.73M | -39.5% |
| Cash & short-term investments | $65.11M | $90.85M | $63.74M | $45.88M | $51.70M | -28.3% |
| Accounts receivable | $29.87M | $23.36M | $26.18M | $31.88M | $32.93M | +27.9% |
| Inventory | $3.99M | $3.60M | $4.04M | $3.97M | $4.99M | +11.0% |
| Total current assets | $106.38M | $126.33M | $103.15M | $89.75M | $97.87M | -15.8% |
| Property, plant & equipment | $4.35M | $4.50M | $4.65M | $4.80M | $5.33M | -3.2% |
| Total assets | $111.32M | $131.42M | $108.42M | $96.23M | $104.88M | -15.3% |
| Total current liabilities | $134.23M | $117.30M | $92.06M | $87.16M | $99.22M | +14.4% |
| Current debt | $40.31M | $32.23M | $21.01M | $12.75M | $30.73M | +25.1% |
| Long-term debt | $209.63M | $192.16M | $205.88M | $176.74M | $152.25M | +9.1% |
| Total debt | $256.19M | $230.87M | $233.61M | $196.42M | $190.62M | +11.0% |
| Total liabilities | $441.49M | $397.06M | $401.34M | $365.49M | $343.81M | +11.2% |
| Retained earnings | -$1.85B | -$1.78B | -$1.76B | -$1.66B | -$1.62B | -3.8% |
| Shareholder equity | -$330.17M | -$265.65M | -$292.93M | -$269.26M | -$238.93M | -24.3% |
| Working capital | -$27.86M | $9.03M | $11.09M | $2.59M | -$1.35M | -408.4% |
| Net tangible assets | -$330.17M | -$265.65M | -$292.93M | -$269.26M | -$238.93M | -24.3% |
| Shares issued | 22.68M | 22.54M | 18.31M | 8.70M | 8.57M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$67.02M | -$22.39M | -$102.20M | -$33.13M | -$37.25M | -199.3% |
| Depreciation & amortisation | -$3.00K | $12.00K | $19.00K | $121.00K | $78.00K | -125.0% |
| Stock-based compensation | $1.93M | $3.01M | $3.90M | $2.80M | $3.78M | -35.8% |
| Change in working capital | $1.27M | $3.85M | $5.50M | $14.25M | $10.05M | -67.0% |
| Operating cash flow | -$24.93M | -$22.73M | -$11.83M | -$5.86M | -$18.70M | -9.7% |
| Investing cash flow | -$10.04M | $3.20M | $5.00M | $4.80M | $18.29M | -413.6% |
| Financing cash flow | -$898.00K | $49.80M | $29.69M | $0 | $356.00K | -101.8% |
| Free cash flow | -$24.93M | -$22.73M | -$11.83M | -$5.86M | -$18.70M | -9.7% |
| End cash position | $55.30M | $91.17M | $60.89M | $38.02M | $39.08M | -39.3% |
Options analytics
Put / call volume
1.63
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-23.1% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+50.0%
Puts bid over calls
Call volume
38
Contracts, this expiry
Put volume
62
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.39 | -2.32 | -66.9% |
| Mar 2026 | -1.44 | -1.24 | +14.1% |
| Dec 2025 | -2.00 | -2.23 | -11.4% |
| Sep 2025 | -3.25 | -3.82 | -17.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.32 | 2 | $33.54M | -23.8% |
| Next quarter | -1.21 | 2 | $34.31M | +0.7% |
| Current year | -5.85 | 2 | $135.63M | -7.1% |
| Next year | -2.82 | 2 | $173.57M | +28.0% |
Analyst targets & ownership
Mean target$7.25
High target$11.00
Low target$3.00
Implied upside966.18%
Analyst count4
ConsensusNONE
Strong buy / Buy2 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders4.67%
Held by institutions97.03%
Institutions holding136
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.21
-43.96% from price
SMA 20
1.46
-55.55% from price
SMA 50
2.04
-68.19% from price
SMA 100
5.52
-87.68% from price
SMA 200
6.66
-90.24% from price
EMA 12
1.17
-41.75% from price
EMA 26
1.61
-57.85% from price
EMA 50
2.65
-74.33% from price
RSI (14)
17.4
Oversold
MACD (12,26,9)
-0.45
Hist -0.03
ATR (14)
0.18
28.08% of price
Realised vol 30D
147.3%
Annualised
Bollinger upper
2.26
20, 2σ
Bollinger lower
0.67
20, 2σ
50 / 200 cross
Death
2.04 vs 6.66
Trend bias
Below 200
-90.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.06
Largely independent
Realised vol 30D
147.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-93.9%
Peak to trough
Max drawdown 5Y
-99.7%
Peak to trough
ATR 14
0.18
28.08% of price
Beta (reported)
1.04
5Y monthly, from filing
Short interest
Shares short
7.87M
Prior 9.64M
Change vs prior
-18.4%
Shorts covering
% of float
34.85%
Heavily shorted
% of shares out
34.68%
Against total outstanding
Days to cover
6.0
Crowded exit
Float
16.01M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 31, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| May 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 27, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 30, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 25, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Mar 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 10, 26 | Rodman & Renshaw | INITIATED | — | Buy |
| Feb 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 5, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Nov 4, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Oct 13, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:15
Split dateFeb 26, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-08-31
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-05-28
Offering Registrations
S-8 · 2026-05-27
Headlines
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 5d ago
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · 26d ago
Selinexor Sales Forecast and Market Size Analysis to 2034 | Selinexor Market Poised for Growth as Phase III Myelofibrosis Results Open New Commercial Opportunities
GlobeNewswire · 27d ago
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
Simply Wall St. · 33d ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 35d ago
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
PR Newswire · 37d ago
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock
Insider Monkey · 46d ago
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.